466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies

I.M. Quetglas; Roser Pinyol; Daniel Dauch; Anna Portela; Alberto Villanueva; Judit Peix; María Ángeles Moreno de la Higuera; Agrin Moeini; Jessica Zucman‐Rossi; Manel Esteller; Vincenzo Mazzaferro; Lars Zender; Josep M. Llovet

doi:10.1016/s0959-8049(14)70592-1

Related publications

Article2015

P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Judit Peix, Mónica Higuera, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

Journal of Hepatology

Article2016

Re-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc

Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Sara Torrecilla, Victoria Tovar, Agrin Moeini, Clara Alsinet, Silvana Bonilla, Anna Portela, Leonardo Rodríguez‐Carunchio, María A. Solé, A. Villanueva, Manel Esteller, Lars Zender, Josep M. Llovet

Journal of Hepatology

Article2017

TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

I.M. Quetglas, Daniela Sia, Jiao Yan, Moe Maeda, M. Castro, Manel Esteller, Josep M. Llovet

Journal of Hepatology

Article2008

2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES

Victoria Tovar, Clara Alsinet, Laia Cabellos, María A. Solé, A. Villanueva, Derek Y. Chiang, Susana Moyano, M. Schwartz, Vincenzo Mazzaferro, Jordi Bruix, Josep M. Llovet

Journal of Hepatology

Article2018

Precision medicine targeting disrupted IGF signaling in hepatoblastoma

Olga Kuchuk, Nicholas K. Akers, Daniela Sia, Marina Simon‐Coma, Jose Carrillo, Iris Martinez-Quetglas, Martina Gambato, Laura Royo, Stephen Yoo, M.A. Buendia, Stefano Cairo, Jinhong Zhu, Vincenzo Mazzaferro, Bojan Losic, Carolina Armengol, Josep M. Llovet

Journal of Hepatology

466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies

Abstract

Discussion(0)

Related publications

P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies

Re-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc

TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES

Precision medicine targeting disrupted IGF signaling in hepatoblastoma